Objective: Regulation of growth hormone (GH) receptor expression and hence tissue GH sensitivity may be important for the conflicting results found in treatment studies with recombinant growth hormone in chronic heart failure (CHF). Growth hormone-binding protein (GHBP) corresponds to the extracellular domain of the GH receptor and is closely related to measures of body composition and, specifically, to size of visceral fat tissue. Leptin, the adipocyte specific (ob) gene product, has been proposed as the signal linking adipose tissue and GHBP/GH-receptor expression. CHF has recently been shown to be a hyperleptinaemic and insulin-resistant state regardless of aetiology. This study aimed to examine the influence of leptin on GHBP in CHF patients with and without cardiac cachexia compared with healthy control subjects. Methods: We studied 47 male patients with CHF (mean age 61^2 years, New York Heart Association (NYHA)-class 2:7^0:1, left ventricular ejection fraction (LVEF) 28^2%, peak oxygen consumption 16:8^0:9 ml=kg=min) and 21 male healthy controls of similar age. Of the CHF patients, 19 were cachectic (cCHF; non-oedematous weight loss .7.5% over at least 6 months) and 28 non-cachectic (ncCHF; similar for age and LVEF). Insulin sensitivity was assessed by an intravenous glucose tolerance test using the minimal model approach. Results: Compared with healthy controls, patients had elevated levels of leptin (7:6^0:7 vs 4:8^0:7 ng=ml, P , 0:05), insulin (76:2^8:9 vs 41:4^6:0 pmol=l, P , 0:01), and reduced insulin sensitivity (2:43^0:2 vs 3:48^0:3 min 21 :mU:ml 21 :10 4 , P , 0:005) but similar GHBP levels (901^73 vs 903^95 pmol=l). Leptin levels were increased in ncCHF (9:11^1:0 ng=ml, P ¼ 0:001) but were not different from normal in cCHF (5:32^0:7 ng=ml, P . 0:5). After correction for total body fat mass, both ncCHF and cCHF were hyperleptinaemic (41:8^3:8 and 37:9^0:38 vs 24:4^2:1 ng=ml=100 g, ANOVA P ¼ 0:001). In both patients and controls there was a direct correlation between leptin levels and GHBP (r ¼ 0:70 and r ¼ 0:71 respectively, both P , 0:0001). This relationship was stronger than between GHBP and several parameters of body composition (body mass index (BMI), total and regional body fat mass or % body fat) and held true when sub-groups were tested individually (ncCHF r ¼ 0:62, P , 0:001; cCHF r ¼ 0:79, P , 0:0001). In multivariate regression analysis in all CHF patients, serum leptin levels emerged as the strongest predictor of GHBP, independent of age, BMI, total and regional fat mass or % body fat, fasting insulin level and insulin sensitivity. Conclusion: Fat mass corrected leptin levels are elevated in CHF patients with and without cachexia. Reduced total fat mass may account for lower leptin levels in cachectic CHF patients compared with non cachectic patients. Leptin strongly predicts GHBP levels in CHF regardless of its hyperleptinaemic state or severely altered body composition as in cardiac cachexia. Leptin could be the signalling link between adipose tissue and GHBP/GH receptor expression in CHF.
Introduction
The high-affinity growth hormone-binding protein (GHBP) is derived from membrane bound growth hormone (GH) receptors by proteolytic cleavage and is identical to the extra-cellular binding domain of the receptor (1 -3) . It is regarded as an intrinsic part of the growth hormone -insulin-like growth factor-I (GH -IGF-I) axis as it is thought to reflect tissue-bound GH receptor status (4) . The use of recombinant human growth hormone as a novel therapeutic approach in chronic heart failure (CHF) showed, despite a convincing concept, no significant clinical effect (5) . Acquired GH resistance may be an important feature in subgroups of CHF patients and could explain the diverse responses to GH therapy seen in different patients (6) . It has been suggested that low GHBP levels represent a quantitative tissue GH receptor deficiency as one of the molecular mechanisms of GH resistance (7) . The regulation of GH receptor expression is complex and more work is needed in order to improve our understanding of the regulation of the GH -IGF-I axis. Nutritional status has been found to play an important role in the regulation of the GH axis and a direct relationship between GHBP and several measures of body composition and, specifically, the size of abdominal adipose tissue has consistently been reported (8 -11) . There is increasing evidence that leptin, the adipocyte specific (ob) gene product, might be the link between adipose tissue and the GH-receptor/GHBP expression (12) . Initially seen as a mediator of central regulation of food intake and energy expenditure, recent studies have demonstrated that leptin receptors are expressed in several peripheral tissues such as pancreatic islets, liver, kidney, lung and skeletal muscle (13 -15) , suggesting that leptin may have a physiological role in the regulation of energy metabolism also on a peripheral level. It has been shown in both children (16) and adults (17) that leptin strongly relates to GHBP levels and it has been suggested that leptin may be the signal regulating GH-receptor/GHBP expression (12) . Furthermore, insulin sensitivity and secretion have also been reported to influence plasma GHBP activity (18) and are, in turn, themselves closely related to leptin (19) . The clinical significance of leptin in humans is, however, not fully understood as studies in rodent animal models might not be fully comparable with human physiology (20) .
It is now well established that CHF is not merely a haemodyamic disorder but rather is a syndrome that also has significant neuroendocrine (21), immune (22) and metabolic disturbances (23) . We have recently shown that CHF is a hyperleptinaemic (24) insulin resistant state characterised by both fasting and stimulated hyperinsulinaemia which is independent of aetiology (25) . With deterioration of CHF cardiac cachexia may occur. This complication of the CHF syndrome is characterised by an imbalance of catabolic/anabolic hormones, suggestive of acquired GH resistance (26) resulting in a general loss of tissue (i.e. lean, adipose and bone) and impaired survival (27) . The clinical significance of elevated leptin levels in CHF is not known but its close relationship to the GH -IGF-I axis, body composition and energy metabolism suggest an important role of leptin for metabolic homeostasis.
This study aimed to examine the influence of leptin on GHBP in CHF patients compared with healthy volunteers. Interrelation with insulin sensitivity and body composition with special attention to cardiac cachexia was also taken into account.
Subjects and methods

Patient population
The study group consisted of 47 male patients with CHF due to ischaemic heart disease ðn ¼ 28Þ or idiopathic dilated cardiomyopathy ðn ¼ 19Þ, and 21 healthy male control subjects of similar age. The diagnosis of CHF was based on a history of CHF with symptomatic exercise limitation for at least 6 months. In all patients, objective evidence of left ventricular enlargement or functional impairment by radionuclide ventriculography and/or echocardiography was present. Medication was individually optimized, all patients were treated as clinically indicated with angiotensin converting enzyme inhibitors or angiotensin II receptor antagonists, diuretics, digitalis, nitrates, calcium antagonists, aspirin and warfarin in varying combinations. At the time of the study patients were free of peripheral oedema and did not have significantly raised jugular venous pressure or hepatomegaly. Cardiac cachexia defined as a non-intentional, non-oedematous weight loss of more than 7.5% over a period of at least 6 months was documented (27) . In the CHF group, 19 patients were considered as being cachectic. These patients had no signs of other primary cachectic states like cancer, hyperthyroidism or liver cirrhosis. Patients with chronic lung disease, neuromuscular disorders, myocardial infarction in the preceding 3 months, signs of acute infection, symptomatic peripheral vascular disease or excessive alcohol intake were also excluded from the study. All patients and healthy volunteers gave written informed consent and the study was approved by the local Ethics Committee.
Assessments
Blood samples were collected in the morning between 0800 h and 0930 h following overnight fasting and after 20 min of supine rest prior to the intravenous glucose tolerance test (ivGTT). All samples were processed immediately after withdrawal and stored at 280 8C until analysis. Within 24 h of the ivGTT, all patients underwent maximal cardiopulmonary treadmill exercise testing (modified Bruce protocol) using a respiratory mass spectrometer (Amis 2000, Odense, Denmark) and a standard inert gas dilution technique for assessment of peak oxygen consumption, as described previously (28) .
Intravenous glucose tolerance test
Participants underwent an ivGTT with sampling at 16 time points during 180 min, as previously described and validated against the euglycaemic clamp method in patients with CHF (29) . Glucose was administered intravenously as a 50% solution, at a dose of 0.5 g/kg body weight over 3 min. The ivGTT was used to assess insulin and glucose dynamics and the insulin sensitivity index (S I ) was calculated using the minimal model approach according to Bergman et al. (30) . Insulin and glucose concentrations during the ivGTT were expressed as incremental areas under the concentration profile areas, calculated using the trapezium rule. S I , the inverse to insulin resistance, is defined as the fraction of the glucose distribution space cleared per minute by insulin-dependent glucose disposal relative to the concentration of insulin. This is estimated as a physiological constant, characteristic for any given individual, and is expressed in min 21 .mU.ml 21 .10 4 .
Body fat distribution
Total and regional fat and lean tissue mass were estimated by dual energy X-ray absorptiometry (DEXA) employing a Lunar DPX (Lunar Corp., Madison, WI, USA). Total body scans were analysed using the extended research mode to obtain total and regional fat measurements of the trunk, arms and legs. The trunk region was delineated by an upper horizontal border below the chin, vertical borders lateral to the ribs, including all soft tissue but excluding the arms, and a lower border formed by oblique lines passing through the hip joints. The leg region was defined as the tissue below the oblique lines passing through the hip joints and the arm region was defined as the tissue lateral to the vertical borders of the trunk region. All scans were performed and analysed using version 3.6z software (Lunar Corp.). Precision of lean tissue measurements was ,2% and fat tissue measurements was ,5% for the machine used in our institution (31) . Body mass index (BMI) was calculated in the usual way as the ratio of weight (kg) and squared height (m 2 ).
Laboratory determinations
GHBP was measured in duplicate employing a ligand immunofunctional assay (LIFA) similar to the assay described earlier (32) using glycosilated GHBP as a calibrator and Europium fluorescence for endpoint determination. Serum leptin was measured in duplicate using a commercially available radioimmunoassay kit (Linco Research, Inc., St Charles, MO, USA). The antibody used was a polyclonal rabbit antibody raised to highly purified human leptin. The sensitivity of this test is 0.5 ng/ml, the intra-assay coefficient of variation was 3.4% (interassay coefficient of variation: 4.7%). Total immunoreactive insulin was measured in batches on samples stored at 220 8C by double antibody radioimmunoassay (Guildhay Ltd, Guildford, Surrey, UK). Within-and between-batch coefficients of variation ranged between 4 and 6%. The other parameters including plasma glucose, sodium, creatinine and catecholamines were analysed using standard hospital analysis procedures.
Statistical analyses
Results are presented as mean values^s:e:m: (unless otherwise stated). ANOVA and unpaired Student's t-test were used as appropriate. When ANOVA showed significant differences, Fisher's post hoc test was applied. A probability-value of P , 0:05 was considered statistically significant. Due to the skewed distribution, metabolic variables were log-transformed appropriately for statistical analysis (33) . Due to the close dependence of leptin on body fat mass, leptin levels are also reported adjusted for the respective individuals' total body fat mass. To analyse relationships between variables, bivariate correlation analyses, simple linear (least square method) and multivariate regression analyses were performed (StatView 4.5, Abacus Concepts Inc., Berkeley, CA, USA). Due to the increased number of statistical tests for regression analyses, a more stringent P-value of P , 0:01 was considered statistically significant.
Results
CHF patients and healthy control subjects were similar for age, BMI and total and regional fat distribution (all P . 0:2, Table 1 ). Patients had higher serum leptin levels (+57%, P , 0:05), higher fasting insulin levels (+84%, P , 0:01) and reduced insulin sensitivity (230%, P , 0:005) compared with controls. When comparing leptin levels of both groups after correction for total body fat mass, the difference was even more pronounced (+65%, P , 0:0005). There was no difference in GHBP levels between both groups. CHF patients were sub-grouped as being cachectic and non-cachectic, with clinical and anthropometrical characteristics of both sub-groups compared with controls given in Table 2 . Cachectic patients (cCHF) showed significant differences in body composition and fat distribution compared with controls but no differences were found between controls and non-cachectic CHF patients (ncCHF) except for leg fat tissue. Fasting insulin levels were increased in non-cachectic (+111%, P ¼ 0:003) but not significantly in cachectic patients (+43%; P ¼ 0:1) compared with controls, and insulin sensitivity was reduced by 32% in ncCHF ðP ¼ 0:006Þ and 26% in cCHF ðP ¼ 0:04Þ compared with healthy controls. Leptin levels were increased in non-cachectic patients (+89%, P ¼ 0:002) but were not significantly different in cachectic patients (+10.1%, P . 0:2, Fig.  1a ) compared with controls. After correction for total body fat mass, leptin levels in both non-cachectic and cachectic CHF patients were significantly increased compared with normal subjects (ncCHF: +72%, cCHF: +56%; both P , 0:005, Fig. 1b) . GHBP was higher in ncCHF and lower in cCHF compared with controls. Although failing to reach statistical significance (ANOVA: P ¼ 0:15), there was a trend for lower GHBP levels in cCHF compared with ncCHF ðP ¼ 0:051Þ. There was no significant difference between non-cachectic and cachectic patients with regard to aetiology of CHF and New York Heart Association (NYHA)-class. Both groups were also similar in terms of mean left ventricular ejection fraction and peak oxygen consumption.
Correlation analyses
Associations between leptin and several parameters of body composition for both patients and controls are listed in Table 3 . Bivariate correlation analyses showed a strong direct relationship of leptin and various parameters of body composition, especially total and trunk fat mass.
We subsequently analysed the relationship between GHBP and these body composition parameters, leptin, fasting insulin and insulin sensitivity ( Table 4 ). The correlation was noted to be strongest between GHBP and serum leptin (controls: r ¼ 0:71, P , 0:001, CHF: r ¼ 0:70, P , 0:0001, Fig. 2 ). When patient subgroups were analysed, the correlation held true in both noncachectic and cachectic patients and was strongest for cachectic patients (cCHF: r ¼ 0:79, P , 0:0001, ncCHF: r ¼ 0:62, P , 0:001). Multivariate regression analysis for prediction of GHBP levels substantiated the impact of leptin as an independent predictor of GHBP in CHF. In several models we combined serum leptin levels with age and with fat mass related parameters of body composition, fasting insulin, and insulin sensitivity as independent variables in all CHF patients (Table 5 ). In all models tested, leptin was consistently found to be the strongest predictor of GHBP independent of age and parameters of body fat mass. Apart from a trend for BMI, no fat mass related parameter tested (i.e. total body fat mass, trunk fat mass, total body and percentage trunk fat, fasting insulin levels and insulin sensitivity) significantly contributed to predict GHBP in the respective models.
Discussion
The main finding in the present study is that, similar to healthy subjects, serum leptin levels are a strong predictor of GHBP in CHF patients, independent of age and parameters of body composition such as weight, BMI, and total and regional body fat mass. This correlation also holds true when hyperleptinaemia is present and also when there is a severe disturbance of body composition as is the case in cardiac cachexia. This finding is in keeping with previous reports which have shown that GHBP depends directly on serum leptin levels (16, 17) and therefore supports the hypothesis that leptin may be the signalling link between body adipose tissue and GH-receptor/GHBP expression (12) .
The previously reported strong association between leptin and fat tissue has been confirmed in our study population (Table 2 ). Leptin is regarded as being a central mediator of energy balance through its effects on receptors in the central nervous system, influencing satiety and energy expenditure (13, 34) . The recent finding that leptin receptors are as well expressed in tissue other than the brain (13 -15, 35) suggested that leptin might also be involved in the regulation of metabolism on a peripheral level. To our knowledge, this is the first study to report on the relationship between leptin and GHBP in CHF patients with and without cardiac cachexia. It is known that serum leptin Figure 1 Upper panel: Plasma leptin levels in healthy controls, and in non-cachectic (ncCHF) and cachectic (cCHF) chronic heart failure patients. Lower panel: Leptin levels corrected for body fat mass in controls, ncCHF and cCHF patients. levels are higher in women than in men, independent of its strong association with adipose tissue (36) , and there are gender-based differences in the regulation of leptin in humans (37) . To prevent our results from being biased by these confounding factors we decided to study only male subjects. GHBP is identical to the extracellular binding domain of the GH-receptor (1) and is thought to result from Figure 2 Relation between plasma leptin levels and GHBP in patients with chronic heart failure; **log transformation result in asymmetric scales. (W) Non-cachectic CHF patients, (.) cachectic CHF patients. Table 5 Multivariate regression analysis of GHBP as dependent variable in relation to leptin, age and several anthropometric parameters in chronic heart failure patients. proteolytic cleavage from the membrane bound receptor (3), being seen as an indirect measure of tissue-bound GH receptor status (4) . As a plasma protein, GHBP may modulate GH action by binding circulating GH and thus protecting it from degradation and increasing its half life (38) . On the other hand, the intravascular binding of GH by GHBP may also prohibit the passage of GH into the extravascular compartment and the binding of GH to tissue receptors. The GH -IGF-I axis is closely related to nutritional status and therefore an effect of body composition on GHBP levels may be expected. In our study, GHBP levels differ between the three groups investigated, showing higher levels in non-cachectic patients and reduced levels in the cachectic group as compared with controls. There was a strong trend for lower GHBP levels in cachectic patients compared with non-cachectic CHF patients ðP ¼ 0:051Þ. These differences, however, do not reach the level of statistical significance. This could be explained, in part, by the known wide variation of GHBP between individuals and the small number of subjects tested. In a larger study, the differences for GHBP between the groups may well become significant. Another explanation might be represented by the elevated serum leptin levels we found in heart failure patients. This finding is in keeping with our previous observation that CHF is a hyperleptinaemic state (24) . In the present study, we extend this previous report to show significant differences of serum leptin levels between non-cachectic and cachectic patients. Non-cachectic CHF patients have elevated leptin levels in comparison to healthy controls. In cachectic patients serum leptin levels are significantly lower than in non-cachectic patients and are in fact not statistically different from control values. This is in line with reports from others showing decreased leptin levels in cachectic CHF patients compared with non-cachectic patients (39, 40) . However, when leptin levels were expressed after correction for total body fat mass, cachectic patients were also found to be significantly hyperleptinaemic as compared with healthy control subjects. Given the strong association between serum leptin levels and size of adipose tissue (see Table 3 ) and the reduced mass of adipose tissue in cachectic patients, the decreased leptin levels in cachectic CHF patients may be viewed as pseudo normal levels. In their study, Murdoch and co-workers (39) corrected leptin for percentage body fat mass which, we believe, is problematic as: (a) all compartments rather than solely adipose tissue change in cardiac cachexia (27) , and (b) leptin production relates to total mass of adipose tissue and not to its relative contribution to body composition. White adipose tissue is the main source of leptin in humans and synthesis of this hormone in a given volume of fat tissue may also be abnormally upregulated in the state of cardiac cachexia (Fig. 1b) . Our study shows that the strong correlation between leptin and GHBP remains stable when leptin levels are abnormally elevated and in patients with a severely reduced amount of body fat mass as in cardiac cachexia. This supports the suggestion that the relationship between GHBP and leptin is not merely a by-product of the metabolic balance in healthy human physiology but rather a distinct characteristic of metabolic regulation. This is in keeping with the hypothesis of leptin being a regulating factor for the expression of tissue GH receptor (12) . In view of the novel therapeutic approach using recombinant human GH in CHF (5), our study sheds more light on potential mechanisms for the regulation of tissue GH sensitivity. Reduced GH sensitivity (i.e. GH resistance) might be an explanation for the inefficiency of this GH treatment seen in some CHF patients (6) . Deficient tissue GH receptor expression, represented by low circulating GHBP levels, might be one of the molecular mechanisms of acquired GH resistance (7) . Other disease states associated with acquired GH resistance, such as acute fasting (41), chronic malnutrition (42) and insulin-dependent diabetes mellitus (43) also have reduced serum GHBP activity. So far, the cachectic state or leptin levels have not been reported in the GH treatment studies. Whether additional administration of leptin to amplify the effect of GH treatment is a viable therapeutic option as compared with other possibilities to overcome GH resistance such as high dose therapy, an optimised dose regime (44) or a combination therapy of GH and IGF-I needs to be evaluated in future studies.
Independent variables
We cannot explain from the results of the present study the cause for the up-regulation of leptin in CHF patients. Recently, Nordfors et al. (45) reported on elevated leptin levels in patients with chronic renal failure due to decreased plasma clearance. In our study, we did not find a correlation between serum leptin levels and serum creatinine levels. This does not entirely exclude a possible role of impaired renal function for hyperleptinaemia in CHF, but it is unlikely to be a dominant factor. One could speculate that without the up-regulated leptin production in these patients, GHBP levels would be even more reduced in cardiac cachexia. Whether the up-regulated leptin levels could be viewed as a mechanism to prevent further reduction of GH receptor/GHBP expression cannot be interpreted from these results. The regulatory interrelations of leptin with several metabolic pathways are, however, complex and far from well understood. Since our current knowledge of the role of leptin in regulating metabolic balance is mainly based on rodent animal models, more studies in humans are needed to elucidate further the regulatory pathways of which leptin is a component (20) .
In summary, we have demonstrated that in male CHF patients, similar to healthy control subjects, serum leptin levels strongly and directly predict GHBP independently of age and total and regional amounts of fat tissue. This correlation also holds true in patients with cardiac cachexia where the hyperleptinaemia (as seen in non-cachectic CHF patients) seems to return to normal due to dramatically reduced fat tissue (i.e. pseudo-normalisation). When corrected for body fat mass, cachectic patients also show increased leptin levels as do non-cachectic patients. Our findings support the hypothesis that leptin might indeed be an important regulatory factor for GH receptor/GHBP expression.
